Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis.

Sharpley FA, De-Silva D, Mahmood S, Sachchithanantham S, Ramsay I, Garcia Mingo A, Worthington S, Hughes D, Mehta A, Kyriakou C, Griffiths PD, Wechalekar AD.

Eur J Haematol. 2019 Dec 9. doi: 10.1111/ejh.13366. [Epub ahead of print]

PMID:
31815313
2.

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.

Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, Lachmann HJ, Quarta C, Fontana M, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD.

Blood. 2019 Dec 19;134(25):2271-2280. doi: 10.1182/blood.2019000834.

PMID:
31578202
3.

A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.

Sharpley FA, Petrie A, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Martinez-Naharro A, Quarta C, Hawkins PN, Wechalekar AD.

Br J Haematol. 2019 Dec;187(5):642-652. doi: 10.1111/bjh.16143. Epub 2019 Aug 13.

PMID:
31410841
4.

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.

Sharpley FA, Fontana M, Martinez-Naharro A, Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Hawkins PN, Wechalekar AD.

Haematologica. 2019 Aug 8. pii: haematol.2019.217695. doi: 10.3324/haematol.2019.217695. [Epub ahead of print]

5.

Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.

Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Yong K, Rabin N, Popat R, Kyriakou C, Worthington S, Sharpley F, Smith M, Shah R, Cheesman S, Hawkins PN, Wechalekar AD.

Br J Haematol. 2019 Dec;187(5):638-641. doi: 10.1111/bjh.16122. Epub 2019 Aug 6.

PMID:
31388995
6.

Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis.

Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, Gritti M, Quarta C, Knight DS, Wechalekar AD, Lachmann HJ, Perlini S, Pontone G, Moon JC, Kellman P, Gillmore JD, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 1):69-80. doi: 10.1016/j.jcmg.2019.03.026. Epub 2019 Jun 12.

PMID:
31202744
7.

Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.

Rezk T, Lachmann HJ, Fontana M, Naharro AM, Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Hawkins PN, Gillmore JD.

Br J Haematol. 2019 Aug;186(3):460-470. doi: 10.1111/bjh.15955. Epub 2019 May 24.

PMID:
31124579
8.

Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.

Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD.

Circulation. 2019 Jul 2;140(1):16-26. doi: 10.1161/CIRCULATIONAHA.118.038169. Epub 2019 May 21. Erratum in: Circulation. 2019 Jul 30;140(5):e185.

PMID:
31109193
9.

Spinal Stenosis in Familial Transthyretin Amyloidosis.

Carr AS, Shah S, Choi D, Blake J, Phadke R, Gilbertson J, Whelan CJ, Wechalekar AD, Gillmore JD, Hawkins PN, Reilly MM.

J Neuromuscul Dis. 2019;6(2):267-270. doi: 10.3233/JND-180348.

PMID:
30856118
10.

The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis.

Rezk T, Gilbertson JA, Mangione PP, Rowczenio D, Rendell NB, Canetti D, Lachmann HJ, Wechalekar AD, Bass P, Hawkins PN, Bellotti V, Taylor GW, Gillmore JD.

J Pathol Clin Res. 2019 Jul;5(3):145-153. doi: 10.1002/cjp2.126. Epub 2019 Apr 2.

11.

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis.

Sharpley FA, Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, Whelan CJ, Fontana M, Hawkins PN, Wechalekar AD.

Blood Cancer J. 2019 Feb 4;9(2):16. doi: 10.1038/s41408-019-0180-1. No abstract available.

12.

A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement.

Manwani R, Page J, Lane T, Burniston M, Skillen A, Lachmann HJ, Gillmore JD, Fontana M, Whelan C, Hawkins PN, Wagner T, Wechalekar AD.

Amyloid. 2018 Dec;25(4):247-252. doi: 10.1080/13506129.2018.1552852. Epub 2019 Jan 19.

PMID:
30661419
13.

Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0102-7.

PMID:
30568288
14.

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Jan;15(1):45-59. doi: 10.1038/s41581-018-0077-4. Erratum in: Nat Rev Nephrol. 2019 Feb;15(2):121.

PMID:
30510265
15.

Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis.

Ross JC, Hutt DF, Burniston M, Page J, Steeden JA, Gillmore JD, Wechalekar AD, Hawkins PN, Fontana M.

Amyloid. 2018 Sep;25(3):203-210. doi: 10.1080/13506129.2018.1520087.

PMID:
30486686
16.

Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis.

Rezk T, Davenport A, Gan JJ, Lachmann HJ, Fontana M, Martinez-Naharro A, Sachchithanantham S, Guillotte C, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Hawkins PN, Gillmore JD.

Br J Haematol. 2019 Jun;185(5):977-980. doi: 10.1111/bjh.15675. Epub 2018 Nov 18. No abstract available.

PMID:
30450572
17.

The genomic landscape of plasma cells in systemic light chain amyloidosis.

Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, Johnson SK, Bauer MA, Weinhold N, Kaiser MF, Johnson DC, Jones JR, Pawlyn C, Proszek P, Schinke C, Facon T, Dumontet C, Davies FE, Morgan GJ, Walker BA, Wechalekar AD.

Blood. 2018 Dec 27;132(26):2775-2777. doi: 10.1182/blood-2018-08-872226. Epub 2018 Nov 16. No abstract available.

PMID:
30446495
18.

Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience.

Rowczenio D, Quarta CC, Fontana M, Whelan CJ, Martinez-Naharro A, Trojer H, Baginska A, Ferguson SM, Gilbertson J, Rezk T, Sachchithanantham S, Mahmood S, Manwani R, Sharpley F, Wechalekar AD, Hawkins PN, Gillmore JD, Lachmann HJ.

Hum Mutat. 2019 Jan;40(1):90-96. doi: 10.1002/humu.23669. Epub 2018 Nov 1.

PMID:
30328212
19.

Myocardial Edema and Prognosis in Amyloidosis.

Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, Knight DS, Zumbo G, Rosmini S, Maestrini V, Bulluck H, Rakhit RD, Wechalekar AD, Gilbertson J, Sheppard MN, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

J Am Coll Cardiol. 2018 Jun 26;71(25):2919-2931. doi: 10.1016/j.jacc.2018.03.536.

20.

Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.

Manwani R, Sachchithanantham S, Mahmood S, Foard D, Sharpley F, Rezk T, Lane T, Quarta C, Fontana M, Lachmann HJ, Gillmore JD, Whelan C, Hawkins PN, Wechalekar AD.

Blood. 2018 Aug 16;132(7):761-764. doi: 10.1182/blood-2018-04-846493. Epub 2018 Jun 20. No abstract available.

PMID:
29925500
21.

Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.

Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Kotecha T, Francis R, Rezk T, Quarta CC, Whelan CJ, Lachmann HJ, Wechalekar AD, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2019 May;12(5):823-833. doi: 10.1016/j.jcmg.2018.02.016. Epub 2018 Apr 18.

PMID:
29680336
22.

Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds.

Wagner T, Page J, Burniston M, Skillen A, Ross JC, Manwani R, McCool D, Hawkins PN, Wechalekar AD.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1129-1138. doi: 10.1007/s00259-018-3995-2. Epub 2018 Apr 12.

23.

Biomarkers in AL amyloidosis: is the summit in sight?

Wechalekar AD.

Blood. 2018 Apr 5;131(14):1502-1503. doi: 10.1182/blood-2018-02-832113. No abstract available.

PMID:
29622535
24.

Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis.

Rezk T, Gilbertson JA, Rowczenio D, Bass P, Lachmann HJ, Wechalekar AD, Fontana M, Mahmood S, Sachchithanantham S, Whelan CJ, Wong J, Rendell N, Taylor GW, Hawkins PN, Gillmore JD.

Nephrol Dial Transplant. 2018 Feb 1;33(2):241-247. doi: 10.1093/ndt/gfw375.

PMID:
29401357
25.

Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.

Rowczenio DM, Pathak S, Arostegui JI, Mensa-Vilaro A, Omoyinmi E, Brogan P, Lipsker D, Scambler T, Owen R, Trojer H, Baginska A, Gillmore JD, Wechalekar AD, Lane T, Williams R, Youngstein T, Hawkins PN, Savic S, Lachmann HJ.

Blood. 2018 Mar 1;131(9):974-981. doi: 10.1182/blood-2017-10-810366. Epub 2017 Dec 28.

26.

Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein.

Rowczenio D, Stensland M, de Souza GA, Strøm EH, Gilbertson JA, Taylor G, Rendell N, Minogue S, Efebera YA, Lachmann HJ, Wechalekar AD, Hawkins PN, Heimdal KR, Selvig K, Lægreid IK, Demoulin N, Aydin S, Gillmore JD, Wien TN.

Kidney Int Rep. 2016 Nov 19;2(3):461-469. doi: 10.1016/j.ekir.2016.11.005. eCollection 2017 May.

27.

Role of 99m Tc-DPD scintigraphy in imaging extra-cardiac light chain (AL) amyloidosis.

Sachchithanantham S, Hutt DF, Quigley AM, Hawkins P, Wechalekar AD.

Br J Haematol. 2018 Nov;183(3):506-509. doi: 10.1111/bjh.14988. Epub 2017 Oct 30. No abstract available.

PMID:
29082513
28.

Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.

Sachchithanantham S, Berlanga O, Alvi A, Mahmood SA, Lachmann HJ, Gillmore JD, Hawkins PN, Harding S, Wechalekar AD.

Br J Haematol. 2017 Nov;179(4):575-585. doi: 10.1111/bjh.14908. Epub 2017 Oct 8.

PMID:
28990174
29.

Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study.

Phillips EH, Nash S, Adedayo T, Whelan CJ, Fontana M, Mahmood S, Lachmann HJ, Gillmore JD, Smith P, Clifton-Hadley L, Hawkins PN, Wechalekar AD.

Amyloid. 2017 Dec;24(4):242-244. doi: 10.1080/13506129.2017.1385453. Epub 2017 Oct 6. No abstract available.

PMID:
28984490
30.

Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology.

Lane T, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ.

Amyloid. 2017 Sep;24(3):189-193. doi: 10.1080/13506129.2017.1352503. Epub 2017 Jul 26.

PMID:
28745926
31.

Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.

Rezk T, Lachmann HJ, Fontana M, Sachchithanantham S, Mahmood S, Petrie A, Whelan CJ, Pinney JH, Foard D, Lane T, Youngstein T, Wechalekar AD, Bass P, Hawkins PN, Gillmore JD.

Kidney Int. 2017 Dec;92(6):1476-1483. doi: 10.1016/j.kint.2017.05.004. Epub 2017 Jul 18.

PMID:
28729034
32.

Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.

Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, Sachchithanantham S, Fontana M, Youngstein T, Quarta CC, Wechalekar AD, Gillmore JD, Hawkins PN, Lachmann HJ.

Amyloid. 2017 Sep;24(3):162-166. doi: 10.1080/13506129.2017.1342235. Epub 2017 Jul 7.

PMID:
28686088
33.

Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis.

Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, Rezk T, Youngstein T, Mahmood S, Sachchithanantham S, Lachmann HJ, Fontana M, Whelan CJ, Wechalekar AD, Hawkins PN, Gillmore JD.

Eur Heart J. 2017 Jun 21;38(24):1905-1908. doi: 10.1093/eurheartj/ehx047.

34.

Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis.

Rezk T, Whelan CJ, Lachmann HJ, Fontana M, Sachchithanantham S, Mahmood S, Khan F, Khiani R, Tomson J, Youngstein T, Gillmore JD, Hawkins PN, Wechalekar AD.

Br J Haematol. 2018 Jul;182(1):145-148. doi: 10.1111/bjh.14747. Epub 2017 May 9. No abstract available.

PMID:
28485005
35.

CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy.

Martinez-Naharro A, Abdel-Gadir A, Treibel TA, Zumbo G, Knight DS, Rosmini S, Lane T, Mahmood S, Sachchithanantham S, Whelan CJ, Lachmann HJ, Wechalekar AD, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M.

JACC Cardiovasc Imaging. 2018 Jan;11(1):152-154. doi: 10.1016/j.jcmg.2017.02.012. Epub 2017 Apr 12. No abstract available.

36.

High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study.

Mahmood S, Sovani M, Smith P, George L, Quarta CC, Sachchithanantham S, Fontana M, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD.

Sleep Med. 2017 Apr;32:191-197. doi: 10.1016/j.sleep.2016.11.021. Epub 2016 Dec 21.

PMID:
28366333
37.

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis.

Wechalekar AD, Whelan C.

Blood Cancer J. 2017 Mar 24;7(3):e546. doi: 10.1038/bcj.2017.26. No abstract available.

38.

Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.

Hutt DF, Fontana M, Burniston M, Quigley AM, Petrie A, Ross JC, Page J, Martinez-Naharro A, Wechalekar AD, Lachmann HJ, Quarta CC, Rezk T, Mahmood S, Sachchithanantham S, Youngstein T, Whelan CJ, Lane T, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD.

Eur Heart J Cardiovasc Imaging. 2017 Dec 1;18(12):1344-1350. doi: 10.1093/ehjci/jew325.

PMID:
28159995
39.

Diagnosing Light Chain Amyloidosis on Temporal Artery Biopsies for Suspected Giant Cell Arteritis.

Ghinai RA, Mahmood S, Mukonoweshuro P, Webber S, Wechalekar AD, Moore SE.

J Neuroophthalmol. 2017 Mar;37(1):34-39. doi: 10.1097/WNO.0000000000000447. Review.

PMID:
27556960
40.

Comparison of Free Light Chain Assays:  Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis.

Mahmood S, Wassef NL, Salter SJ, Sachchithanantham S, Lane T, Foard D, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD.

Am J Clin Pathol. 2016 Jul;146(1):78-85. doi: 10.1093/ajcp/aqw079. Epub 2016 Jun 27.

PMID:
27353767
41.

Autosomal dominant familial Mediterranean fever in Northern European Caucasians associated with deletion of p.M694 residue-a case series and genetic exploration.

Rowczenio DM, Iancu DS, Trojer H, Gilbertson JA, Gillmore JD, Wechalekar AD, Tekman M, Stanescu HC, Kleta R, Lane T, Hawkins PN, Lachmann HJ.

Rheumatology (Oxford). 2017 Feb;56(2):209-213. doi: 10.1093/rheumatology/kew058. Epub 2016 May 5.

PMID:
27150194
42.

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN.

Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.

PMID:
27143678
43.

European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.

Sachchithanantham S, Roussel M, Palladini G, Klersy C, Mahmood S, Venner CP, Gibbs S, Gillmore J, Lachmann H, Hawkins PN, Jaccard A, Merlini G, Wechalekar AD.

J Clin Oncol. 2016 Jun 10;34(17):2037-45. doi: 10.1200/JCO.2015.63.3123. Epub 2016 Apr 25.

PMID:
27114592
44.

Response to Letters Regarding Article, "Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis".

Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC.

Circulation. 2016 Mar 22;133(12):e450-1. doi: 10.1161/CIRCULATIONAHA.116.021162. No abstract available.

45.

(99m)Tc-DPD scintigraphy as a novel imaging modality for identification of skeletal muscle amyloid deposition in light-chain amyloidosis.

Hutt DF, Gilbertson J, Quigley AM, Wechalekar AD.

Amyloid. 2016 Jun;23(2):134-5. doi: 10.3109/13506129.2016.1158160. Epub 2016 Mar 16. No abstract available.

PMID:
26981883
46.

Systemic amyloidosis.

Wechalekar AD, Gillmore JD, Hawkins PN.

Lancet. 2016 Jun 25;387(10038):2641-2654. doi: 10.1016/S0140-6736(15)01274-X. Epub 2015 Dec 21. Review.

PMID:
26719234
47.

Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.

Mahmood S, Bridoux F, Venner CP, Sachchithanantham S, Gilbertson JA, Rowczenio D, Wagner T, Sayed R, Patel K, Fontana M, Whelan CJ, Lachmann HJ, Hawkins PN, Gillmore JD, Wechalekar AD.

Lancet Haematol. 2015 Jun;2(6):e241-50. doi: 10.1016/S2352-3026(15)00068-X. Epub 2015 May 6.

PMID:
26688234
48.

Role of imaging in cardiac amyloidosis: An ongoing challenge.

Wechalekar AD.

J Nucl Cardiol. 2016 Dec;23(6):1364-1367. Epub 2015 Nov 5. No abstract available.

PMID:
26542989
49.

Natural history and outcome of light chain deposition disease.

Sayed RH, Wechalekar AD, Gilbertson JA, Bass P, Mahmood S, Sachchithanantham S, Fontana M, Patel K, Whelan CJ, Lachmann HJ, Hawkins PN, Gillmore JD.

Blood. 2015 Dec 24;126(26):2805-10. doi: 10.1182/blood-2015-07-658872. Epub 2015 Sep 21.

50.

Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.

Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC.

Circulation. 2015 Oct 20;132(16):1570-9. doi: 10.1161/CIRCULATIONAHA.115.016567. Epub 2015 Sep 11.

Supplemental Content

Loading ...
Support Center